Based on studies involving APP/PS1 transgenic mice, FGF-21 has been shown to reduce Aβ plaque deposition and suppress pathological tau hyperphosphorylation in AD model mice by modulating monocarboxylate transporter-dependent metabolic pathways [93]. This evidence concerns the gene APP and Alzheimer disease.